Tremelimumab in Melanoma

Drug class Target Agent Diseases Line of Therapy Status Source
CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody CTLA-4 tremelimumab melanoma metastatic Trials complete with results Ribas et al. 2013

The CTLA-4 inhibitor tremelimumab has previously been investigated in patients with melanoma. The only phase III clinical trial of tremelimumab to date was published in 2013, and it failed to show a statistically significant improvement in overall survival when patients with previously untreated metastatic melanoma were treated with tremelimumab compared to standard chemotherapy alone (NCT00257205; Ribas et al. 2013).


Reference Study Type / Phase Line of Treatment Treatment Agent Mutation Status # Patients in Study Response Rate PFS (months) OS (months)
Ribas et al. 2013 Phase III 1st tremelimumab   328 10.7% 20.3 (6-month PFS) 12.6
dacarbazine or temozolamide   327 9.8% 18.1 (6-month PFS) 10.7
NOTE: OS = overall survival; PFS = progression-free survival

 

Contributors: Wade T. Iams, M.D., Douglas Johnson, M.D., Christine M. Lovly, M.D., Ph.D.

Suggested Citation: Iams, W.T., D. Johnson, C. Lovly. 2015. Immunotherapy in Cancer. My Cancer Genome http://www.padiracinnovation.org/content/molecular-medicine/c49085-melanoma/ (Updated February 10).​​​​​​​​​​​

Last Updated: June 24, 2015

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.